KV
Therapeutic Areas
Agios Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PYRUKYND (mitapivat) | Pyruvate kinase (PK) deficiency — adults | Approved |
| AG-946 | Hemolytic anemias and other indications | Phase 2 |
| Multiple undisclosed preclinical programs | Undisclosed rare diseases | Preclinical |
| IDHIFA (enasidenib) — DIVESTED | Relapsed/refractory AML with IDH2 mutation | Approved |
| TIBSOVO (ivosidenib) — DIVESTED | Relapsed/refractory AML with IDH1 mutation | Approved |
Leadership Team at Agios Pharmaceuticals
BG
Brian Goff
Chief Executive Officer
SG
Sarah Gheuens, M.D., Ph.D.
Chief Medical Officer, Head of R&D
CJ
Cecilia Jones
Chief Financial Officer
TM
Tsveta Milanova
Chief Commercial Officer
EL
Ellen Lopresti
Chief People Officer
JB
Jim Burns
Chief Legal Officer
RB
Rahul Ballal, Ph.D.
Board Member; CEO of Mediar Therapeutics, Inc.
JC
Jeffrey Capello
Independent Board Member; Former CFO of Biogen
KF
Kaye Foster
Independent Board Member; Former SVP Global HR at Onyx Pharmaceuticals
DS
David Schenkein, M.D.
Former Chief Executive Officer (2009–2019), Co-founder